Gene preparation based on alpha-hemolysin and application thereof
By expressing and targeting α-hemolysin gene preparations in cells, the problems of low selectivity and immune rejection of α-hemolysin in the prior art are solved, and efficient killing and immune activation of a variety of tumor cells are achieved. It has wide application prospects.
Patent Information
- Application Number
- CN202310609371.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-26
- Publication Date
- 2024-11-26
AI Technical Summary
The existing α-hemolysin gene preparations have low selectivity for tumor cells, and exogenous proteins cause immune rejection, which limits their application in tumor treatment. No studies have reported mediating α-hemolysin in cells. Gene preparations that are internally expressed and act on subcellular structures to exert tumor-killing effects.
Develop a gene preparation that mediates the overexpression of α-hemolysin in cells, targets organelles rather than cell membranes, mediates the enrichment of α-hemolysin in organelles such as Golgi or mitochondria through recombinant plasmids and non-viral gene delivery systems. to achieve tumor cell killing.
This gene preparation significantly improves the killing effect on tumor cells, overcomes hemolytic and immunogenic side reactions, activates anti-tumor immunity, has stronger therapeutic effects and safety, and is suitable for a variety of tumor cells.
Smart Images

Figure CN119020409A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a gene preparation, in particular to a gene preparation based on alpha-hemolysin and application thereof, belonging to the technical field of anti-tumor gene drugs. Background Art
[0002] α-hemolysin is a strong pore-forming toxin secreted by Staphylococcus aureus. It is one of the important virulence factors of Staphylococcus aureus. It can assemble on the cell membrane to form a heptamer pore structure, thereby destroying the integrity of the cell membrane and causing cell lysis. Studies have shown that α-hemolysin has strong anti-tumor activity against tumors such as breast cancer. However, α-hemolysin has low selectivity for tumor cells. Local injection in vivo is prone to cause tissue necrosis, intravenous injection is prone to cause severe hemolysis and vasculitis, and it may also cause strong immune rejection reactions because it is an exogenous protein, which seriously limits its application in tumor treatment. Gene therapy provides a new method for tumor treatment. Several gene therapy drugs have been approved for marketing in China, the United States, the European Union and other countries. The gene delivery system can effectively mediate the expression of plasmids encoding α-hemolysin in vivo. By taking advantage of the fact that gene therapy drugs have different material bases from the protein molecules they encode, gene drugs encoding α-hemolysin are designed for tumor treatment, which provides a new method for improving the drugability of α-hemolysin for tumor treatment.
[0003] Existing gene preparations all introduce the gene encoding α-hemolysin into bacteria, and exert anti-tumor effects by mediating the secretion of α-hemolysin and destroying the tumor cell membrane. The invention patent with application number 201680032071.7 discloses engineered bacteria for the production and release of therapeutic substances. Through genetic engineering, the therapeutic polypeptide gene containing hemolysin is introduced into the bacteria, so that the polypeptide is released when the desired density is reached, thereby killing tumor cells or inhibiting the growth of tumor cells. The invention patent with application number 201880057532.5 discloses a bacterium that targets tumors and treats cancer. The bacterium includes a nucleic acid system and genes encoding cytotoxins including Escherichia coli α-hemolysin, which can effectively inhibit tumors.
[0004] At present, there are no reports on gene preparations that mediate the expression of α-hemolysin in cells and act on subcellular structures to kill tumors. Our research found that α-hemolysin mediated by gene delivery system can be enriched in the Golgi apparatus, destroy the Golgi apparatus structure, and efficiently kill a variety of tumor cells, with a killing effect significantly better than secretory gene preparations; at the same time, by adding organelle targeting signal peptides, α-hemolysin can be mediated to other organelles such as mitochondria to exert anti-tumor effects. Based on this, we have invented a new anti-tumor gene preparation based on α-hemolysin that targets organelles, which is highly innovative and has good application prospects. Summary of the invention
[0005] In view of the above defects, the technical problem solved by the present invention is to provide a gene preparation that mediates the expression of α-hemolysin in cells, targeting organelles rather than cell membranes, so that it has a stronger killing effect on tumor cells.
[0006] The invention is based on a gene preparation of alpha-hemolysin, wherein the alpha-hemolysin is derived from Staphylococcus aureus. The gene preparation mediates the overexpression of the alpha-hemolysin in cells, and the alpha-hemolysin is mainly enriched in the cell organelles rather than the cell membrane.
[0007] In a specific embodiment, the organelle is a Golgi apparatus, a mitochondria or an endoplasmic reticulum.
[0008] In a specific embodiment, the gene preparation includes a recombinant plasmid, wherein the recombinant plasmid includes a gene sequence encoding α-hemolysin and a eukaryotic vector, wherein the gene sequence encoding α-hemolysin is a gene sequence without a signal peptide or with an organelle targeting signal peptide.
[0009] In a specific embodiment of the present invention, the α-hemolysin-based gene preparation further comprises a delivery system.
[0010] In one embodiment, the delivery system is a non-viral gene delivery system.
[0011] In a specific embodiment, the delivery system comprises liposomes, polymers, micelles, nanoparticles or exosomes.
[0012] The present invention also provides the use of the gene preparation based on α-hemolysin in the preparation of anti-tumor drugs.
[0013] The gene preparation based on α-hemolysin of the present invention targets and enriches in the Golgi apparatus to kill tumor cells, and has a wide range of killing effects on different tumor cells. In addition, the gene preparation can also activate anti-tumor immunity, induce cells to produce stronger immunogenic death, and show stronger immune activation ability in in vivo treatment models.
[0014] In a specific embodiment of the present invention, the tumor is skin cancer, bladder cancer, glioma, medulloblastoma, liver cancer, lung cancer, gastric cancer, colorectal cancer, cervical cancer, ovarian cancer, nasopharyngeal cancer, esophageal cancer, oral cancer, breast cancer, prostate cancer, thyroid cancer, retinoblastoma, bone cancer or pancreatic cancer.
[0015] Compared with the prior art, the present invention has the following beneficial effects:
[0016] 1. The present invention constructs for the first time an α-hemolysin gene preparation mediated by a non-viral delivery system, which can mediate the expression of α-hemolysin in cells and specifically act on the Golgi apparatus to induce tumor cell death. This gene drug has better safety than protein preparations, can overcome the side effects of α-hemolysin protein preparations in terms of hemolysis and immunogenicity to a certain extent, and can be regulated by the delivery system to target tumor cells.
[0017] 2. The gene preparation of the present invention can destroy the Golgi apparatus and kill tumor cells, and has a wide range of killing effects on different tumor cells.
[0018] 3. The gene preparation of the present invention can activate anti-tumor immunity and induce cells to produce stronger immunogenic death. It has demonstrated stronger immune activation ability in the in vivo treatment model and can be used as an anti-tumor gene drug.
[0019] 4. The gene preparation of the present invention can achieve targeting to other organelles by modifying the recombinant plasmid therein, such as targeting mitochondria to kill tumor cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 Schematic diagram of the construction of the recombinant plasmid in Example 1 of the present invention. Wherein A is pVAX1-α-hemolysin carrying a signal peptide SP+ Schematic diagram of recombinant plasmid; B is pVAX1-α-hemolysin without signal peptide SP- Schematic diagram of recombinant plasmid; C is DPP / pVAX1-α-hemolysin SP- Transmission electron microscopy images of nanoparticles; D is B16-F10 cells treated with DPP / α-hemolysin sp- 、DPP / α-hemolysin sp+ A, DPP / pVAX1, and NS treatment for 48 hours to detect the expression of α-hemolysin by western blot; E is the white light and fluorescence images of B16-F10 transfected with DPP / α-hemolysinSP+-GFP and DPP / α-hemolysinSP+-GFP 24 hours later. Scale bar, 100μm.
[0021] Figure 2 DPP / α-hemolysin SP- The growth inhibition effect diagram of tumor cells at the cellular level. Among them, A is B16-F10, A549, HepG2, Hela, UMUC-3, SKOV3, A375 after NS, DPP / pVAX, DPP / α-hemolysin SP+ or DPP / α-hemolysinSP- MTT assay of cell viability after 48h treatment; B is HepG2, Hela, A549, UMUC-3, NS, DPP / pVAX, DPP / α-hemolysin SP+ or DPP / α-hemolysin SP- White light image after 48h of treatment, scale bar: 100μm.
[0022] Figure 3 In Example 3 of the present invention, α-hemolysin sp- -The mechanism of action of GFP in tumor cells. A is α-hemolysin SP- Localization map in B16-F10 cells, scale bar: 5μm; B is α-hemolysin SP- Co-localization with Golgi apparatus in Hela and HepG2 cells, scale bar: 5 μm; C is the transmission electron microscopy observation of B16-F10 cells in DPP / pVAX and DPP / α-hemolysin SP- The morphological changes of Golgi apparatus after transfection, scale bar: 1μm.
[0023] Figure 4 Intratumoral injection of DPP / α-hemolysin in Example 4 of the present invention SP- Figure 4 In vivo antitumor activity of the nanocomplex.
[0024] Among them, A is the change diagram of tumor size and tumor volume, mean ± standard deviation, n = 5; B is the representative H&E image and Ki67 staining image of tumor tissue in each group, scale: 50 μm.
[0025] Figure 5 This is a T cell analysis diagram in Example 4 of the present invention. A is the flow cytometry analysis of CD4+T cells / CD8+T cells infiltrating in tumor tissue; B is the statistical data of CD4+T cells infiltrating in tumor tissue; C is the statistical data of CD8+T infiltrating in tumor tissue; D is the staining of tumor tissue sections with CD4 and CD8 antibodies, scale: 50μm. Mean ± standard deviation, n = 3.
[0026] Figure 6 This is a graph showing the antitumor activity of the DPP / α-hemolysinSP-nanocomplex in the contralateral melanoma tumor model in Example 5 of the present invention. A is the tumor volume, tumor size and tumor weight of the right tumor; B is the tumor volume, tumor size and tumor weight of the left tumor, mean ± standard deviation, n = 5.
[0027] Figure 7The immune cell analysis diagram in the left tumor in Example 5 of the present invention. A is a flow cytometry analysis of CD4+T cells / CD8+T cells infiltrating in tumor tissue; B is a flow cytometry analysis of NK1.1+NK cells infiltrating in tumor tissue; C is a statistical diagram of CD4+T cells infiltrating in tumor tissue; D is a statistical diagram of CD8+T cells infiltrating in tumor tissue; E is a statistical diagram of NK1.1+NK cells infiltrating in tumor tissue. Mean ± standard deviation, n = 3.
[0028] Figure 8 α-hemolysin in Example 6 of the present invention sp- The gene preparation inhibits the growth of subcutaneous lung cancer tumors. A is the tumor size; B is the change of tumor volume during treatment; C is the tumor weight; D is the H&E staining of tumor tissue, scale, 50μm, mean ± standard deviation, n = 5.
[0029] Fig. 9 α-hemolysin in Example 7 of the present invention MTS Evaluation of the ability of gene preparations to kill tumor cells in vitro. A is a graph showing the ability of B16-F10 cells to kill tumor cells after DPP / α-hemolysin MTS A, DPP / pVAX1, and the expression of α-hemolysin detected by western blot after 48h of treatment with normal saline (NS); B is the expression of α-hemolysin in B16F10 cells MTS -GFP co-localization with mitochondria. C) B16-F10 cells treated with DPP / α-hemolysin MTS 、DPP / α-hemolysin sp- 、DPP / α-hemolysin sp+ , DPP / pVAX1, and LDH release was detected after treatment with normal saline (NS) for 48 hours. DETAILED DESCRIPTION
[0030] The invention is based on a gene preparation of alpha-hemolysin, mediates the overexpression of alpha-hemolysin in cells, and targets the enrichment in the cell organelles rather than the cell membrane; the alpha-hemolysin is derived from Staphylococcus aureus.
[0031] The gene preparation based on α-hemolysin of the present invention may include plasmid DNA, mRNA and the like.
[0032] In a specific embodiment, the organelle is a Golgi apparatus, a mitochondria or an endoplasmic reticulum.
[0033] In a specific embodiment, the gene preparation includes a recombinant plasmid, wherein the recombinant plasmid includes a gene sequence encoding α-hemolysin and a eukaryotic vector, wherein the gene sequence encoding α-hemolysin is a gene sequence without a signal or with an organelle targeting signal peptide.
[0034] The present invention constructs for the first time a gene preparation for the intracellular expression of α-hemolysin mediated by a non-viral delivery system. When the recombinant plasmid encoding α-hemolysin is not modified with any signal peptide, the gene preparation can mediate the intracellular expression of α-hemolysin and specifically act on the Golgi apparatus to induce tumor cell death. When the recombinant plasmid carries an organelle targeting signal peptide, the gene preparation can target the organelles and specifically act on the organelles, thereby killing tumor cells. For example, when the recombinant plasmid carries a signal peptide targeting mitochondria, the gene preparation can target mitochondria. Compared with secretory α-hemolysin gene preparations, intracellularly expressed α-hemolysin gene preparations exhibit a stronger killing effect on tumor cells.
[0035] In a specific embodiment of the present invention, the amino acid sequence encoding α-hemolysin is shown in Sequence 1.
[0036] In a specific embodiment of the present invention, the gene sequence encoding α-hemolysin is shown in Sequence 2, wherein the first 60 bases are a signal peptide sequence, as shown in Sequence 3.
[0037] The gene preparation of the present invention can mediate the expression of α-hemolysin in cells. In a specific embodiment, the eukaryotic vector is at least one of pVAX1, pcDNA3.1, and pSV2.
[0038] In a specific embodiment of the present invention, the α-hemolysin-based gene preparation further comprises a delivery system.
[0039] Gene delivery systems commonly used in the art are all applicable to the present invention, including viral delivery systems and non-viral vector delivery systems. In a specific embodiment, the delivery system is a non-viral gene delivery system. In some preferred embodiments, the delivery system includes liposomes (such as lipo3000), polymers (such as PEI25K), micelles, nanoparticles (such as ZIF-8) or exosomes.
[0040] In a specific embodiment, the delivery system is DOTAP-mPEG-PLA nanoparticles (abbreviated as DPP nanoparticles), see the record of patent ZL201510925693.X for details.
[0041] The present invention also provides the use of the gene preparation based on α-hemolysin in the preparation of anti-tumor drugs.
[0042] The gene preparation based on α-hemolysin of the present invention targets and enriches in the Golgi apparatus to kill tumor cells, and has a wide range of killing effects on different tumor cells. In addition, the gene preparation can also activate anti-tumor immunity, induce cells to produce stronger immunogenic death, and show stronger immune activation ability in in vivo treatment models.
[0043] In a specific embodiment of the present invention, the tumor is bladder cancer, blood cancer, bone cancer, bone marrow cancer, brain cancer / nervous system cancer, breast cancer, colorectal cancer, esophageal cancer, gastrointestinal cancer, head cancer, kidney cancer, liver cancer, lung cancer, nasopharyngeal cancer, neck cancer, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, testicular cancer, tongue cancer or uterine cancer.
[0044] In a specific embodiment, the α-hemolysin-based gene preparation comprises a recombinant plasmid modified with a mitochondrial targeting signal peptide, and the amino acid sequence of the signal peptide is: MSVLTPLLLRGLTGSARRLPVPRAKIHSL.
[0045] In a specific embodiment, the mitochondrial-targeted gene formulation based on α-hemolysin can mediate the expression of α-hemolysin to mitochondria and produce a strong killing effect on tumor cells.
[0046] The specific implementation modes of the present invention are further described below in conjunction with embodiments, but the present invention is not limited to the scope of the embodiments.
[0047] Example 1
[0048] Design and construct a vector for expressing α-hemolysin. The sequence of α-hemolysin was taken from NCBI (GenBank: AAA26598.1). The first 60 bases are signal peptide sequences. To facilitate its eukaryotic expression and secretion, we selected the hIL-2 signal peptide (the base sequence is shown in Sequence 3) to replace its original signal peptide, and optimized the codons. The optimized codon sequence is shown in Sequence 2. Subsequently, a total synthesis method was used to construct pVAX1-α-hemolysin carrying secretion signal peptides using pVAX1 as a vector and HindIII and XhoI as restriction sites. SP+ Recombinant plasmid (hereinafter referred to as α-hemolysin SP+ ), and pVAX1-α-hemolysin without a signal peptide sp- Recombinant plasmid (hereinafter referred to as α-hemolysin SP- ), see Figure 1 In the figure, A is pVAX1-α-hemolysin carrying the signal peptide SP+Schematic diagram of recombinant plasmid; B is pVAX1-α-hemolysin without signal peptide SP- Schematic diagram of recombinant plasmid. SP- The recombinant plasmid was combined with the delivery system DPP (ZL201510925693.X), and DPP / α-hemolysin was observed under transmission electron microscopy. SP- The nanocomplex was spherical with an average diameter of about 50 nm. B16-F10 cells were seeded in a 6-well plate. SP+ , α-hemolysin SP- The recombinant plasmid (2ug / well) was delivered with system DPP complex (ZL201510925693.X) and transfected. After 48h, the cells were collected and the protein was extracted. The expression of α-hemolysin was detected by Western Blot experiment. The results are shown in Figure 1 D. The results showed that α-hemolysin SP+ , α-hemolysin SP- They are all expressed in tumor cells, among which α-hemolysin sp+ Glycosylation occurs during eukaryotic expression. Deglycosylation enzymes were added during the preparation of samples for immunoblotting experiments, and the experimental results showed that the α-hemolysin protein returned to its normal size. In addition, to further observe the expression and localization of α-hemolysin, we constructed pVAX1-α-hemolysin sp --GFP plasmid and DPP / α-hemolysin sp+ -GFP plasmid. Our cells were transfected with DPP / α-hemolysin in B16-F10 cells. SP+ -GFP and DPP / α-hemolysin SP --GFP, GFP expression can be observed under fluorescence microscopy after 24 hours, among which α-hemolysin SP+ -GFP is distributed in the cytoplasm, while α-hemolysin SP --GFP is concentrated in the cytoplasm in a dot-like manner ( Figure 1 E).
[0049] Example 2
[0050] Melanoma cells B16F10, cervical cancer cells Hela, lung cancer cells A549, melanoma cells A375, ovarian cancer cells Skov3, liver cancer cells HepG2, and bladder cancer cells UMUC-3 were seeded in 96-well plates. SP+ , α-hemolysinSP- After 48h of plasmid transfection (0.15ug / well), cell viability was detected by MTT. The results are shown in Figure 2 A. The results showed that α-hemolysin sp- Significantly inhibits the activity of various tumor cells, α-hemolysin SP- The gene preparation has an inhibition rate of 83% on B16-F10 cell viability, 66% on A549 cell viability, 67% on HepG2 cell viability, 60% on SKOV3 cell viability, 70% on Hela cell viability, 62% on A375 cell viability, 60% on SKOV3 cell viability, and 70% on UMUC-3 cell viability. The inhibitory effect on tumor cells is better than α-hemolysin sp+ 30 hours after transfection, cells were observed under a microscope and α-hemolysin SP- The tumor cells in the treatment group showed obvious necrosis, obvious swelling and vacuolation, see Figure 2 B.
[0051] Example 3
[0052] To observe α-hemolysin sp- To investigate the subcellular organelle localization of hemolysin, we constructed pVAX1-α-hemolysin sp- -GFP plasmid. Use DPP / α-hemolysin sp- -GFP was transfected into B16F10 cells, Hela cells and HepG2 cells respectively, and the cells were fixed with paraformaldehyde after 18 hours. By immunofluorescence staining, anti-GM130 was used to mark the Golgi apparatus, anti-TOMM20 was used to mark the mitochondria, anti-BAP31 was used to mark the endoplasmic reticulum, and anti-LAMP1 / 2 was used to mark the lysosomes. 647 secondary antibody labeling, observation of α-hemolysin under confocal microscope sp- -GFP co-localization with various membrane organelles. The results are shown in the figure. In the three tumor cells, α-hemolysin sp- -GFP is enriched near the Golgi apparatus and co-localizes with the Golgi apparatus to a certain extent. Figure 3 A and Figure 3 B.
[0053] To observe α-hemolysin sp- As described in Example 1, empty pVAX1, α-hemolysin sp-The plasmids were transfected into B16-F10 cells, and the cells were collected and fixed 24 hours later. The samples were prepared and observed by TEM. The results showed that α-hemolysin sp- Severe damage to the Golgi structure, see Figure 3 C.
[0054] Example 4
[0055] Investigation of DPP / α-hemolysin in the B16-F10 subcutaneous melanoma model SP- The in vivo anti-tumor activity of α-hemolysin was tested by intratumoral injection of gene drugs and detection of tumor volume, body weight and other data. sp- The group significantly inhibited the growth of melanoma tumors, and the tumor inhibition rate was 93% ( Figure 4 A) H&E staining and Ki67 staining results showed that DPP / α-hemolysin SP- The mice in the treatment group had fewer Ki67-positive cells in their tumors, lower tumor cell density, and larger tumor cell gaps ( Figure 4 B) Intratumoral injection of DPP / α-hemolysin SP- Nanocomplexes can effectively inhibit tumor growth and reduce tumor malignancy.
[0056] We further analyzed the T cells infiltrating the tumor. The flow cytometry results showed that in the blank control group, CD4+T cells accounted for 0.13% of the tumor tissue, and CD8+T cells accounted for 0.12% of the tumor tissue. In the DPP / pVAX group, CD4+T cells accounted for 0.27% of the tumor tissue, and CD8+T cells accounted for 0.15% of the tumor tissue. SP+ In the group, CD4+T cells accounted for 0.37% of the tumor tissue, CD8+T cells accounted for 0.94% of the tumor tissue, and DPP / α-hemolysin SP- In the treatment group, CD4+T cells accounted for 3.95% of the tumor tissue, and CD8+T cells accounted for 3.55% of the tumor tissue. The infiltration of T lymphocytes was much higher than that in other experimental groups ( Figure 5 , AC). We further detected CD4+T cells and CD8+T cells in tumor tissues by immunofluorescence. More T cell infiltration was observed in the tumor tissues of the DPP / α-hemolysinSP-treated group ( Figure 5 D).
[0057] Example 5
[0058] Evaluation of DPP / α-hemolysin in a bilateral subcutaneous melanoma animal model SP-The ability of the nanocomplex to activate immunogenic death was investigated. Melanoma B16-F10 cells were first inoculated into the left and right flanks of female C57BL / 6 mice, and DPP / α-hemolysin was injected intratumorally. SP- The right tumor was treated with nanocomplexes, with the drug given every other day for a total of 5 times. From the start of drug administration, the volume of the tumors on both sides was recorded every two days. On the 16th day, the tumor tissues of each group were collected and weighed. The results showed that α-hemolysin sp- The group significantly inhibited the growth of right and left melanoma tumors ( Figure 6 A and Figure 6 B). Flow cytometry analysis of immune cells in tumors showed that lymphocyte infiltration in tumors was significantly increased, with CD8+T cells accounting for approximately 3.7% of all cells in tumor tissues, CD4+T cells accounting for approximately 4.9% of all cells in tumor tissues, and NK1.1+NK cells accounting for 1.80% of tumor cells, all significantly higher than those in the empty vector group and α-hemolysin group. sp+ Action Group( Figure 7 ). Description α-hemolysin sp- It can induce immunogenic death of tumors, activate the immune system, and have good distal effects.
[0059] Example 6
[0060] We established an A549 lung cancer subcutaneous tumor model in nude mice and injected DPP / α-hemolysin into the tumor. SP- The results showed that α-hemolysin SP- The group significantly inhibited the growth of subcutaneous lung cancer tumors, and the tumor inhibition rate was 73% calculated based on tumor weight. H&E staining results showed that DPP / α-hemolysin SP- The tumor cell density in the treated group was lower and the gap between tumor cells was larger. The above results showed that DPP / α-hemolysin SP- It has a good effect in inhibiting the growth of subcutaneous lung cancer tumors ( Figure 8 ).
[0061] Example 7
[0062] In order to evaluate the anti-tumor potential of α-hemolysin targeting other organelles, we selected the signal peptide of hCOX8A (the base sequence is shown in SEQ ID NO: 4) to replace its original signal peptide to achieve mitochondrial targeting and optimized the codons. MTS and pVAX1-α-hemolysin MTS-GFP recombinant plasmid (hereinafter referred to as α-hemolysin MTS ). To observe α-hemolysin MTS To investigate the colocalization with mitochondria, we used DPP / α-hemolysin MTS -GFP was transfected into B16F10 cells, and mitochondria were labeled with mitochondrial red fluorescent probe 24 hours later, and then observed under a confocal microscope. Fig. 9 A shows α-hemolysin MTS -GFP can be targeted to mitochondria. α-hemolysin was further detected by Western Blot experiment. MTS Can effectively mediate the expression of α-hemolysin in B16F10 cells ( Fig. 9 B) Targeting of DPP / α-hemolysin to mitochondria was subsequently evaluated by measuring the release of LDH MTS Killing effect on tumor cells B16F10. Fig. 9 C, DPP / α-hemolysin MTS The tumor cell killing effect mediated by DPP / α-hemolysin is stronger than that of secreted DPP / α-hemolysin sp+ Preparation, and intracellular expression of DPP / α-hemolysin targeted to the Golgi sp- The killing effect of the preparations is comparable.
Claims
1. Gene preparation based on α-hemolysin, Features: The α-hemolysin is derived from Staphylococcus aureus. The gene preparation mediates the overexpression of α-hemolysin in cells, and the α-hemolysin is mainly enriched in the cell organelles rather than the cell membrane.
2. The α-hemolysin-based gene preparation according to claim 1, Features: The cell organelle is a Golgi apparatus, a mitochondria or an endoplasmic reticulum.
3. The α-hemolysin-based gene preparation according to claim 1, Features: The gene preparation comprises a recombinant plasmid, wherein the recombinant plasmid comprises a gene sequence encoding alpha-hemolysin and a eukaryotic vector, wherein the gene sequence encoding alpha-hemolysin is a gene sequence without a signal peptide or with a cell organelle targeting signal peptide.
4. The α-hemolysin-based gene preparation according to claim 1, Features: Also included are delivery systems.
5. The α-hemolysin-based gene preparation according to claim 4, Features: The delivery system is a non-viral gene delivery system.
6. The α-hemolysin-based gene preparation according to claim 5, Features: The delivery systems include liposomes, polymers, micelles, nanoparticles or exosomes.
7. Use of the gene preparation based on α-hemolysin according to any one of claims 1 to 6 in the preparation of anti-tumor drugs.
8. Use of the gene preparation based on α-hemolysin according to claim 7 in the preparation of anti-tumor drugs, Features: The gene formulation targets the Golgi apparatus of cells.
9. Use of the gene preparation based on α-hemolysin according to claim 8 in the preparation of anti-tumor drugs, Features: The tumor is skin cancer, bladder cancer, glioma, medulloblastoma, liver cancer, lung cancer, stomach cancer, colorectal cancer, cervical cancer, ovarian cancer, nasopharyngeal cancer, esophageal cancer, oral cancer, breast cancer, prostate cancer, thyroid cancer, retinoblastoma, bone cancer or pancreatic cancer.
